Recent clinical trial results in pancreatic and rectal cancers are challenging long-standing treatment norms, showing unprecedented survival gains and organ preservation potential. Innovations include ...
Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment by targeting dual antigens, addressing tumor heterogeneity. With ...
This lecture will provide an overview of the evolution of the federal definition of Responsible Conduct of Research (RCR), description of some notable cases of RCR violations, ways in which such ...
CTSI Open Research Office sessions feature important topics that can aid those involved in the research process. Through the Open Research Office sessions, Clinical Research Facilitators collaborate ...
Hosted on MSN
New trials offer hope for advanced cancer treatments
A wave of new clinical trial results is bringing cautious optimism to advanced cancer care, with promising data emerging across pancreatic, bowel, rectal, breast, and bladder cancers. Researchers ...
On 28 April 2026, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 will enter into force, representing the most ...
Market opportunities in AI and ML for clinical trials include optimizing trial efficiency, predicting patient outcomes, and supporting adaptive trial designs, all while addressing regulatory and ...
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies -- outcomes not previously observed in SPS ...
“Our clinicians engage in research now. It’s the usual care of the patient, and we generate research information from it.” —Louis Fiore, VA Boston Healthcare System The workshop session on innovations ...
Data sharing and collaboration among experts is a time-tested guide to help practicing clinicians abide by the Food and Drug Administration’s (FDA’s) black box warning. Practicing clinicians, whether ...
The European Medicines Agency (EMA) has taken a similar transparency stance with clinical trials. In October 2023, the EMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results